Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy

IMPORTANCE: Bone resorption inhibitors (BRIs) are recommended by international guidelines to prevent skeletal-related events (SREs) among patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases. Abiraterone acetate with prednisone is currently the most common first-...

Descripción completa

Detalles Bibliográficos
Autores principales: Francini, Edoardo, Montagnani, Francesco, Nuzzo, Pier Vitale, Gonzalez-Velez, Miguel, Alimohamed, Nimira S., Rosellini, Pietro, Moreno-Candilejo, Irene, Cigliola, Antonio, Rubio-Perez, Jaime, Crivelli, Francesca, Shaw, Grace K., Zhang, Li, Petrioli, Roberto, Bengala, Carmelo, Francini, Guido, Garcia-Foncillas, Jesus, Sweeney, Christopher J., Higano, Celestia S., Bryce, Alan H., Harshman, Lauren C., Lee-Ying, Richard, Heng, Daniel Y. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299314/
https://www.ncbi.nlm.nih.gov/pubmed/34292336
http://dx.doi.org/10.1001/jamanetworkopen.2021.16536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299314/
https://www.ncbi.nlm.nih.gov/pubmed/34292336
http://dx.doi.org/10.1001/jamanetworkopen.2021.16536

Ejemplares similares